Movatterモバイル変換

Ranibizumab

С Википедије, слободне енциклопедије

Ranibizumab
Klinički podaci
Drugs.com	Monografija
Način primene	Intravitrealno
Farmakokinetički podaci
Poluvreme eliminacije	9 dana

Identifikatori
CAS broj	347396-82-1^Y
ATC kod	S01LA04 (WHO)
DrugBank	DB01270^Y
UNII	ZL1R02VT79^Y
KEGG	D05697^Y
ChEMBL	CHEMBL1201825^Y
Hemijski podaci
Formula	C₂₁₅₈H₃₂₈₂N₅₆₂O₆₈₁S₁₂
Molarna masa	48000

Ranibizumab (prodajno imeLucentis) fragment jemonoklonalnog antitela (Fab) izveden iz istog mišjeg antitela kao ibevacizumab (Avastin). On je znatno manji od roditeljskog molekula i bio je podvrgnut procesumaturacije afiniteta da bi se pojačalo vezivanje zaVEGF-A. On jeinhibitor angiogeneze koji je odobren za lečenje "vlažnog" tipa starostnemakularne degeneracije (AMD, ARMD), i uobičajeme forme starosnoggubitka vida.^[1]^[2]^[3]^[2]^[4]^[5]^[6]^[7]

Reference

[уреди |уреди извор]

^IGMT Link:http://imgt.cines.fr/3Dstructure-DB/cgi/details.cgi?pdbcode=1CZ8&Part=Chain Архивирано на веб-сајтуWayback Machine (7. децембар 2008)
^^а ^бGaudreault J, Fei D, Beyer JC, Ryan A, Rangell L, Shiu V, Damico LA: Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina. 2007 Nov-Dec;27(9):1260-6.PMID 18046235
^Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V: Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005 Feb;46(2):726-33.PMID 15671306
^Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ: Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007 Dec;114(12):2179-82.PMID 18054637
^Kourlas H, Abrams P: Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther. 2007 Sep;29(9):1850-61.PMID 18035187
^Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011).„DrugBank 3.0: a comprehensive resource for omics research on drugs”.Nucleic Acids Res.39 (Database issue): D1035—41.PMC 3013709 .PMID 21059682.doi:10.1093/nar/gkq1126. уреди
^David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008).„DrugBank: a knowledgebase for drugs, drug actions and drug targets”.Nucleic acids research.36 (Database issue): D901—6.PMC 2238889 .PMID 18048412.doi:10.1093/nar/gkm958. уреди